FLRG-242 is a specialized synthetic research peptide derived from follistatin-related gene constructs, designed for evaluating TGF-beta superfamily signaling, myostatin interaction, and receptor binding kinetics in vitro. Supplied exclusively for laboratory and preclinical research, FLRG-242 provides empirical investigators with a highly purified tool for dissecting cellular growth pathways.
FLRG-242 is a specialized synthetic research peptide derived from follistatin-related gene constructs, designed for evaluating TGF-beta superfamily signaling, myostatin interaction, and receptor binding kinetics in vitro. Supplied exclusively for laboratory and preclinical research, FLRG-242 provides empirical investigators with a highly purified tool for dissecting cellular growth pathways.
FLRG-242 is a truncated domain variant based on the follistatin-related gene (FLRG, also recognized in scientific literature as FSTL3 or Follistatin-like 3). Naturally occurring FLRG functions as a secreted glycoprotein that binds and neutralizes specific members of the transforming growth factor-beta (TGF-beta) superfamily, most notably Activin A, Activin B, and myostatin (GDF-8). FLRG-242 represents a optimized molecular sequence synthesized to isolate specific domain interactions without the full-length structural complexity of wild-type glycoproteins.
In laboratory research settings, the flrg-242 peptide is utilized to model ligand-receptor inhibition profiles. By binding extracellular ligands prior to their engagement with activin type II receptors (ActRIIA and ActRIIB), research models evaluate how selective domain neutralization alters downstream Smad2/3 phosphorylation cascade events. Researchers investigating muscle biochemistry, metabolic homeostasis, and extracellular matrix remodeling utilize FLRG-242 to establish baseline kinetic measurements in standardized cellular assays.
Because structural modifications in short-chain peptide variants can alter affinity constants, FLRG-242 serves as a precise control and test compound in microplate binding assays, surface plasmon resonance (SPR) studies, and recombinant protein interaction mapping. Understanding its molecular behavior yields insights into how targeted domain peptides can modulate pathways typically governed by larger endogenous regulatory proteins.
The primary mechanism of action associated with FLRG-242 involves competitive sequestering of circulating growth and differentiation factors. Preclinical literature indicates that FLRG and its engineered derivatives contain tandem follistatin-like N-terminal domains that form high-affinity complexes with Activin A and myostatin. By occluding the receptor-binding epitopes of these ligands, FLRG-242 prevents the assembly of active heterotetrameric receptor complexes on cell membranes.
Under physiological conditions, myostatin and activin signal through transmembrane serine/threonine kinase receptors, inducing intracellular phosphorylation of Smad2 and Smad3. Once phosphorylated, these transcription factors complex with Smad4 and translocate to the nucleus, promoting the transcription of gene networks that inhibit protein synthesis and cellular proliferation. In vitro data indicate that introduction of FLRG-242 to culture media inhibits Smad2/3 phosphorylation in a concentration-dependent manner.
Furthermore, comparative structural studies demonstrate that while native follistatin (FS-315 or FS-288) exhibits strong affinity for cell-surface heparin sulfate proteoglycans, FLRG variants like FLRG-242 demonstrate altered heparin-binding capability. This localized variation allows researchers to study fluid-phase ligand neutralization without high rates of cell-surface sequestration, providing a distinct bio-analytical profile in contrast to native follistatin isoforms available in our all-peptides catalog.
In vitro assays evaluating FLRG-242 primarily focus on myoblast proliferation, differentiation kinetics, and luciferase reporter gene assays linked to Smad-responsive promoters. In C2C12 myoblast culture systems, exposure to recombinant myostatin routinely induces cell cycle arrest and downregulates myogenic markers such as MyoD and myogenin. When co-treated with FLRG-242, preclinical models document a suppression of myostatin activity, resulting in preserved myotube diameter and restored expression of differentiation markers.
Animal model studies exploring follistatin-like signaling networks frequently utilize rodent models to examine metabolic regulation, glucose uptake, and muscle mass preservation during catabolic states. Preclinical studies suggest that central or systemic administration of activin/myostatin antagonists alters body composition parameters, signaling cascades in adipose tissue, and systemic insulin responsiveness. Investigators utilize FLRG-242 to delineate whether these metabolic observations stem directly from Activin A neutralization versus myostatin blockade.
Additional research models utilize FLRG-242 within cardiac cell lines and vascular endothelial cultures. Because TGF-beta signaling pathways regulate fibrotic remodeling in response to ischemic stress, evaluating domain-specific blockers like FLRG-242 provides data regarding collagen deposition, matrix metalloproteinase (MMP) expression, and tissue repair dynamics following simulated hypoxia.
To properly contextualize FLRG-242 within laboratory experimental design, researchers must compare its binding selectivity and structural characteristics against other prominent compounds targeting the myostatin pathway. Prominent comparative compounds include follistatin-344, ace-031, and recombinant antibody constructs such as bimagrumab research models.
Unlike Ace-031, which is a soluble fusion protein composed of the extracellular domain of ActRIIB linked to an Fc region, FLRG-242 is a targeted peptide sequence based on the FSTL3 domain structure. Ace-031 broad-spectrum binding includes BMP-9 and BMP-10 alongside activins, whereas FLRG-242 exhibits a more restricted binding profile favoring Activin A and myostatin with lower off-target BMP cross-reactivity. This selectivity reduces confounding variables in assays where bone morphogenetic protein pathways must remain uninhibited.
Compared to full-length Follistatin-344, FLRG-242 presents a smaller molecular weight, facilitating faster diffusion rates in three-dimensional tissue matrices and organoid cultures. While Follistatin-344 possesses extensive glycosylation patterns that alter in vivo half-life, synthetic FLRG-242 offers an unglycosylated, highly consistent peptide backbone ideal for standardized cell culture media and biochemical titration assays. Researchers evaluating myostatin pathway kinetics often utilize both compounds simultaneously within their experimental matrices to compare full-length native action against domain-isolated inhibition.
Within cellular biology laboratories, FLRG-242 serves as a essential reagent across several core assay formats. High-throughput screening platforms utilize FLRG-242 to benchmark novel small-molecule inhibitors of the TGF-beta family. By establishing standard inhibition curves with FLRG-242, laboratories can evaluate the relative potency and efficacy of uncharacterized experimental compounds.
Key experimental protocols utilizing FLRG-242 include:
1. Western Blotting and Phospho-Protein Analysis: Assessing changes in p-Smad2 and p-Smad3 relative to total Smad levels following treatment with TGF-beta ligands and FLRG-242.
2. Real-Time Quantitative PCR (RT-qPCR): Measuring downstream transcriptional targets such as Pax7, MyoD, Atrogin-1, and MuRF1 in skeletal muscle cell lines.
3. Surface Plasmon Resonance (SPR) and Biolayer Interferometry (BLI): Quantifying the precise equilibrium dissociation constant (Kd), association rate (ka), and dissociation rate (kd) of FLRG-242 binding to Activin A, Activin B, and GDF-8.
4. Cell Viability and Proliferation Assays: Measuring MTT/MTS reduction rates in cultures subjected to catabolic cytokine environments in the presence or absence of the peptide.
To maintain structural stability and prevent premature degradation of FLRG-242, research laboratories must adhere to strict reconstitution and handling procedures. FLRG-242 is typically supplied as a lyophilized (freeze-dried) cake or powder under vacuum or inert gas flush. Prior to opening the vial, the container should be allowed to equilibrate to room temperature to prevent condensation of atmospheric moisture onto the hygroscopic peptide powder.
Reconstitution should be performed using sterile laboratory-grade solvents. For most cell culture assays, reconstituting in sterile bacteriostatic water, sterile normal saline (0.9% NaCl), or standard phosphate-buffered saline (PBS, pH 7.4) is recommended. If solubility challenges occur due to hydrophobic region exposure, short-term solubilization in dilute organic solvents (such as 0.1% acetic acid or minimal DMSO) followed by dilution into aqueous buffer may be required depending on protocol specifications.
Gently swirl or invert the vial to achieve full solution; high-shear mechanical agitation, vigorous shaking, or sonication should be avoided as these forces can induce peptide aggregation or tertiary structural denaturation. Following reconstitution, working aliquots should be prepared immediately using low-protein-binding microcentrifuge tubes to prevent surface adsorption loss.
Lyophilized FLRG-242 should be stored at -20°C or -80°C in a manual defrost freezer for long-term stability. Under proper desiccated storage conditions at -20°C, the lyophilized peptide typically retains chemical integrity and biological activity for up to 24 months from the date of manufacture. Avoid storing reagents in frost-free freezers, as temperature cycling severely compromises peptide bond stability.
Once reconstituted into aqueous solution, FLRG-242 liquid preparations should be kept refrigerated at 2°C to 8°C and used within 7 to 14 days. For extended experimental timelines, reconstituted solutions must be divided into single-use aliquots and stored at -20°C or -80°C to prevent degradation. Multiple freeze-thaw cycles must be rigorously avoided, as repeated phase changes promote protein aggregation, peptide cleavage, and loss of binding stoichiometry.
Detailed guidance on solution handling, storage matrices, and buffer compatibility is cataloged within our comprehensive analytical research hub, providing bench scientists with updated technical reference sheets.
Evaluating research outcomes requires absolute confidence in reagent purity and consistency. Synthetic peptides produced for laboratory evaluation can harbor impurities such as truncated sequences, deletion peptides, un-deprotected side chains, and trace chemical residues from solid-phase peptide synthesis (SPPS). PX1 Research implements rigorous analytical quality control for every lot of FLRG-242.
Purity is verified using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC). RP-HPLC separates the target peptide from related impurities based on hydrophobic interactions, establishing a chromatographic profile. A single sharp peak corresponding to a purity threshold of >=98% ensures that experimental data reflect the action of FLRG-242 rather than synthetic contaminants.
Molecular identity is confirmed via Matrix-Assisted Laser Desorption/Ionization Time-of-Flight (MALDI-TOF) or Electrospray Ionization Mass Spectrometry (ESI-MS). Mass spectrometry measures the exact mass-to-charge ratio (m/z) of the molecule, verifying that the observed molecular weight matches the theoretical sequence calculation. Certificates of Analysis (COA) containing raw HPLC chromatograms and MS spectra are generated for every production lot and made available to institutional buyers through our wholesale institutional pricing portal.
Bacterial endotoxins (lipopolysaccharides, or LPS) represent a major confounding factor in cell culture and preclinical research. Presence of endotoxin in peptide preparations can trigger toll-like receptor 4 (TLR4) activation, inducing non-specific inflammatory signaling cascades, cytokine release, and cellular toxicity that mask or distort the true biological activity of FLRG-242.
PX1 Research subjects every batch of FLRG-242 to rigorous endotoxin quantification using Limulus Amebocyte Lysate (LAL) testing or recombinant Factor C (rFC) assays. Laboratory lots must meet strict limits (typically <0.1 EU/μg peptide) to ensure suitability for sensitive primary cell cultures, stem cell assays, and in vivo animal models.
By enforcing mandatory endotoxin screening alongside HPLC purity and mass verification, PX1 Research guarantees reproducible reagents manufactured in ISO 17025 accredited and GMP-compliant facilities within the USA. All orders ship directly from domestic centers in California and Arizona with same-day handling M–F.
When selecting a supplier for specialized reagents such as FLRG-242, research institutions and laboratory managers must evaluate lot traceability, manufacturing location, and analytical documentation. Research integrity depends on sourcing compounds free of batch-to-batch variation.
PX1 Research specializes exclusively in supplying analytical-grade compounds for laboratory and preclinical research. Every lot is manufactured in the USA, assigned a unique lot number, and accompanied by fully transparent third-party verification documentation. Researchers interested in incorporating FLRG-242 into their experimental workflows can review technical specifications and order directly through our secure platform.
What is the primary research application of FLRG-242?
FLRG-242 is primarily studied in vitro and in preclinical models to examine TGF-beta superfamily signaling, specifically quantifying the binding kinetics and inhibition of Activin A and myostatin (GDF-8).
How does FLRG-242 differ from full-length follistatin?
FLRG-242 is a truncated, domain-specific sequence derived from follistatin-related gene constructs. It offers a smaller molecular mass, altered heparin-binding properties, and more targeted ligand neutralization compared to full-length native follistatin isoforms.
Is FLRG-242 approved for human consumption or therapeutic use?
No. FLRG-242 is sold strictly as a research-grade chemical compound for in vitro, cell culture, and laboratory animal research. It is not intended for human or animal therapeutic, diagnostic, or clinical use.
What purity standard does PX1 Research guarantee for FLRG-242?
PX1 Research guarantees a minimum purity of 98% for FLRG-242, confirmed via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) and mass spectrometry (MS) for every batch.
How should reconstituted FLRG-242 be stored in the lab?
Reconstituted FLRG-242 should be stored in liquid form at 2°C to 8°C for short-term use (up to 7-14 days). For long-term stability, aliquot into single-use vials and store at -20°C or -80°C, avoiding repeated freeze-thaw cycles.
What solvent should be used for reconstituting FLRG-242?
FLRG-242 is commonly reconstituted in sterile bacteriostatic water, sterile phosphate-buffered saline (PBS, pH 7.4), or normal saline (0.9% NaCl), depending on the requirements of the specific cell culture or binding assay.
What is the endotoxin limit for PX1 Research FLRG-242?
Every lot of FLRG-242 undergoes strict LAL or rFC testing to ensure endotoxin levels remain below 0.1 EU/μg, preventing non-specific immune activation in sensitive cell lines.
Where is PX1 Research FLRG-242 manufactured and shipped from?
All PX1 Research peptides are manufactured in GMP-compliant, ISO 17025 accredited facilities in the USA and shipped directly from fulfillment centers located in California and Arizona.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.